Retinal Endo Vascular Surgery for Central Retinal Vein Occlusion

Status Not yet recruiting

Clinical Trial Summary

Patients with Central Retinal Vein Occlusion will undergo vitrectomy, a small needle of about 71 micron will enter a branch retinal vein and TPA will be injected into the obstracted vein.

Clinical Trial Description

Patients with Central Retinal Vein Occlusion less than 6 month duration and reduction of vision to 6/21 will go OCT and FANG examinations.

Patient will be operated vitrectomy, and a branch retinal vein will be punctured by small needle and rTPA 200mcg/ml will be injected to the vein. ;

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00383773
Study type	Interventional
Source	Hadassah Medical Organization
Contact	Michael Halpert, MD.
Phone	00972507874385
Email	halpert@cc.huji.ac.il
Status	Not yet recruiting
Phase	N/A
Start date	October 2006
Completion date	October 2007

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01969708` - Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)	Phase 3
Completed	`NCT02390245` - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study	N/A
Completed	`NCT01231633` - Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)	N/A
Terminated	`NCT00969293` - Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion	Phase 1
Completed	`NCT03981549` - Treatment of Central Retinal Vein Occlusion Using Stem Cells Study	Phase 1/Phase 2
Completed	`NCT02274259` - Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen	Phase 4
Completed	`NCT01360385` - Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With Intravitreal Ranibizumab	N/A
Completed	`NCT00952614` - A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion	N/A
Recruiting	`NCT04601701` - Central Retinal Vein Occlusion (CRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.	N/A
Withdrawn	`NCT03417401` - Surgical Stabilizer Assisted RVC With rtPA for CRVO	Phase 1
Completed	`NCT01976312` - Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)	Phase 3
Completed	`NCT01724554` - Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion	Phase 1/Phase 2
Completed	`NCT01471691` - Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab	Phase 1/Phase 2
Active, not recruiting	`NCT01011374` - Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion	Phase 1
Completed	`NCT03223714` - Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion	Phase 3
Recruiting	`NCT01827722` - Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion	Phase 4
Completed	`NCT00906685` - Bevacizumab for Central Retinal Vein Occlusion Study	Phase 3
Active, not recruiting	`NCT04793100` - Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections	N/A
Recruiting	`NCT02405741` - Hyperbaric Chamber for Central Retinal Vein Occlusion (CRVO) Patients	Phase 2
Recruiting	`NCT01348633` - Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye	N/A